Takeda has been boosted by data showing that its chronic obstructive pulmonary disease therapy Daxas significantly reduced exacerbations and hospitalisations in the severest sufferers.

The REACT study looked at Daxas (roflumilast) in patients with severe COPD who are at risk of frequent and severe exacerbations despite already receiving inhalation therapy with inhaled corticosteroid and long-acting beta agonist combinations or triple (long-acting muscarinic antagonist/ICS/LABA) therapy.

It showed that Daxas significantly reduced the rate of severe exacerbations by 24.3% and those requiring hospitalisation by 23.9%, “reducing the clinical and economic burden of this disease,” Takeda noted. In patients receiving triple therapy, the oral phosphodiesterase 4 (PDE4) enzyme inhibitor cut the rate of severe exacerbations by 23.3%;  the results have been published online in The Lancet.
Klaus Rabe at the University of Kiel said the results reveal Daxas as “the first COPD treatment to decrease the rate of hospitalisation in patients already receiving multiple inhaled treatments”. The once-daily tablet is partnered with Actavis which earlier this month announced it is selling North American rights to roflumilast (sold there as Daliresp) to AstraZeneca.